ADIPOQ and breast carcinoma: The overall results confirmed that postmenopausal breast cancer patients had significantly lower serum adiponectin levels and that lower circulating adiponectin was associated with a higher risk of breast cancer development meaning that adiponectin has a protective effect against this cancer.